戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 A target expands its potential utility as an antigene agent or hybridization probe.
2 The novel TFO can be developed into a potent antigene agent, and its design strategy applied to simil
3    Here we describe a protocol for designing antigene agents and introducing them into cells.
4 ecognition properties which may be useful as antigene agents or tools in molecular biology.
5 ave been extensively studied as antisense or antigene agents that can potentially modulate the expres
6 f the progesterone receptor (PR) function as antigene agents to block PR expression.
7 s are good candidates for further testing as antigene agents.
8 onucleotides have been used as antisense and antigene agents.
9 attractive features as diagnostic probes and antigene agents.
10 omings by serving as effective antisense and antigene agents.
11  of the present work was to characterize the antigene and antiproliferative activity of a triple heli
12 at the c-myc-targeted PS-TFO is an effective antigene and antiproliferative agent, with potential for
13 se of their successful use within antisense, antigene, and other gene-targeting strategies.
14 tions should be considered for antisense and antigene applications.
15 These findings support the feasibility of an antigene approach for the therapeutic regulation of spec
16                     Earlier, we developed an antigene approach, using a type alpha1(I) collagen gene
17 cations to phototriggered antisense-based or antigene-based genetic tools, diagnostic agents and drug
18 the biological activity of TFOs as potential antigene compounds has been limited by cellular uptake.
19 ed (e.g., when PNAs are used as antisense or antigene drugs).
20  antigene peptide nucleic acids (agPNAs) and antigene duplex RNAs (agRNAs) block gene expression and
21              The tumor-selective ganglioside antigene GD2 is frequently expressed on neuroblastomas a
22      To test this hypothesis, we synthesized antigene LNAs (agLNAs) complementary to sequences within
23                           Here, we show that antigene locked nucleic acids (agLNAs) reduce RNA levels
24  chromosomal DNA and that LNAs are bona fide antigene molecules.
25 xo- containing oligomers may find utility as antigene oligonucleotide reagents.
26  BGA002 is a potently improved MYCN-specific antigene oligonucleotide that reverts N-Myc-dysregulated
27                           We have shown that antigene peptide nucleic acids (agPNAs) and antigene dup
28                          A second generation antigene peptide oligonucleotide targeting MYCN induces
29     Here, we evaluated a novel MYCN-specific antigene PNA oligonucleotide (BGA002) in MYCN-amplified
30 plex DNA by strand invasion, suggesting that antigene PNAs (agPNAs) can be important tools for explor
31 y may complicate attempts to identify potent antigene PNAs.
32 Neu, mutants of c-Neu, polyomavirus middle T antigene (PyV-mT), Ras, and bi-transgenic for ErbB2/Neu
33         They are attractive as antisense and antigene reagents, as well as building blocks for molecu
34                                              Antigene RNAs (agRNAs) are small RNA duplexes that targe
35 ulating gene expression by promoter-targeted antigene RNAs (agRNAs) will require identification of th
36                Equally important was that an antigene strategy, the sense PNA, was shown in vivo to b
37 chniques such as in situ hybridization, PCR, antigene targeting, and microarrays.
38 zing ligands, with potential applications in antigene therapeutics.
39 making them highly appealing in the field of antigene therapeutics.
40 otides in biological solutions, antisense or antigene therapies aimed at modulation of specific gene
41                              In the field of antigene therapy, triplex-forming oligonucleotides (TFOs